Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2021
Reporting Period: Second quarter ended June 30, 2021
Context: The registrant is an emerging growth company. This filing announces the results of operations and financial condition for the second quarter of 2021 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not provide specific values for the following metrics:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: Specific financial figures are not present in the provided 8-K text; they are contained within the referenced Exhibit 99.1.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only indicates that results for the second quarter ended June 30, 2021, have been announced.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are expected to be found in the press release attached as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q2 2021 revenue, net loss, and cash burn figures.
- Verify the company's cash position and runway based on the Q2 2021 financial statements.
- Check for any updates on clinical trial progress or partnership announcements mentioned in the press release.
- Confirm if the company has elected to use the extended transition period for emerging growth companies regarding new accounting standards.